BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47-54. [PMID: 10802655 DOI: 10.1038/75586] [Cited by in Crossref: 326] [Cited by in F6Publishing: 334] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Patil MR, Bihari A. A comprehensive study of p53 protein. J Cell Biochem 2022. [PMID: 36183376 DOI: 10.1002/jcb.30331] [Reference Citation Analysis]
2 Marques MA, Andrade GCD, Silva JL, de Oliveira GAP. Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53. Front Mol Biosci 2022;9:944955. [DOI: 10.3389/fmolb.2022.944955] [Reference Citation Analysis]
3 Logotheti S, Pavlopoulou A, Marquardt S, Takan I, Georgakilas AG, Stiewe T. p73 isoforms meet evolution of metastasis. Cancer Metastasis Rev 2022. [PMID: 35948758 DOI: 10.1007/s10555-022-10057-z] [Reference Citation Analysis]
4 Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-wroblewska M. Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas. Cancers 2022;14:3388. [DOI: 10.3390/cancers14143388] [Reference Citation Analysis]
5 Yuan D, Tian J, Fang X, Xiong Y, Banskota N, Kuang F, Zhang W, Duan H. Epidemiological Evidence for Associations Between Genetic Variants and Osteosarcoma Susceptibility: A Meta-Analysis. Front Oncol 2022;12:912208. [DOI: 10.3389/fonc.2022.912208] [Reference Citation Analysis]
6 Hassin O, Nataraj NB, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, Mukherjee S, Maddalena M, Avioz A, Iancu O, Mallel G, Gershoni A, Grosheva I, Feldmesser E, Ben-Dor S, Golani O, Hendel A, Blandino G, Kelsen D, Yarden Y, Oren M. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun 2022;13:2800. [PMID: 35589715 DOI: 10.1038/s41467-022-30481-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang Z, Strasser A, Kelly GL. Should mutant TP53 be targeted for cancer therapy? Cell Death Differ 2022;29:911-20. [PMID: 35332311 DOI: 10.1038/s41418-022-00962-9] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zhang R, Xue M, Yong VW. Central Nervous System Tissue Regeneration after Intracerebral Hemorrhage: The Next Frontier. Cells 2021;10:2513. [PMID: 34685493 DOI: 10.3390/cells10102513] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
9 Lo Piccolo L, Jantrapirom S, Moonmuang S, Teeyakasem P, Pasena A, Suksakit P, Charoenkwan P, Pruksakorn D, Koonrungsesomboon N. In search of TP53 mutational hot spots for Li-Fraumeni syndrome in Asian populations. Trop Med Int Health 2021;26:1401-10. [PMID: 34478609 DOI: 10.1111/tmi.13673] [Reference Citation Analysis]
10 Xia Y, Li X, Sun W. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China. Curr Gene Ther 2020;20:127-41. [PMID: 32951572 DOI: 10.2174/1566523220999200731003206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
11 De Souza C, Madden J, Koestler DC, Minn D, Montoya DJ, Minn K, Raetz AG, Zhu Z, Xiao WW, Tahmassebi N, Reddy H, Nelson N, Karnezis AN, Chien J. Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer. J Natl Cancer Inst 2021:djab019. [PMID: 33555293 DOI: 10.1093/jnci/djab019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Eiholzer RA, Mehta S, Kazantseva M, Drummond CJ, McKinney C, Young K, Slater D, Morten BC, Avery-Kiejda KA, Lasham A, Fleming N, Morrin HR, Reader K, Royds JA, Landmann M, Petrich S, Reddel R, Huschtscha L, Taha A, Hung NA, Slatter TL, Braithwaite AW. Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk. Cancers (Basel) 2020;12:E2472. [PMID: 32882831 DOI: 10.3390/cancers12092472] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Barnoud T, Parris JLD, Murphy ME. Common genetic variants in the TP53 pathway and their impact on cancer. J Mol Cell Biol 2019;11:578-85. [PMID: 31152665 DOI: 10.1093/jmcb/mjz052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
14 Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. J Natl Cancer Inst 2019;111:1202-15. [PMID: 30990221 DOI: 10.1093/jnci/djz051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
15 Yamasaki S, Tani R, Sakurai S, Toratani S, Okamoto T. Oral squamous cell carcinoma of the tongue dorsum with multiple cancer-associated mutations in the TP53 gene. Oral Oncol 2020;109:104774. [PMID: 32451170 DOI: 10.1016/j.oraloncology.2020.104774] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Toufektchan E, Lejour V, Durand R, Giri N, Draskovic I, Bardot B, Laplante P, Jaber S, Alter BP, Londono-Vallejo JA, Savage SA, Toledo F. Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Sci Adv 2020;6:eaay3511. [PMID: 32300648 DOI: 10.1126/sciadv.aay3511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
17 Nassar A, Abouelhoda M, Mansour O, Loutfy SA, Hafez MM, Gomaa M, Bahnassy A, El-Din Youssef AS, Lotfy MM, Ismail H, Ahmed OS, Abou-Bakr AA, Zekri AN. Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. J Adv Res 2020;24:149-57. [PMID: 32322420 DOI: 10.1016/j.jare.2020.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Pavlakis E, Stiewe T. p53's Extended Reach: The Mutant p53 Secretome. Biomolecules 2020;10:E307. [PMID: 32075247 DOI: 10.3390/biom10020307] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
19 Bicker A, Nauth T, Gerst D, Aboouf MA, Fandrey J, Kristiansen G, Gorr TA, Hankeln T. The role of myoglobin in epithelial cancers: Insights from transcriptomics. Int J Mol Med 2020;45:385-400. [PMID: 31894249 DOI: 10.3892/ijmm.2019.4433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
20 Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, To KF. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. Int J Mol Sci 2019;20:E5999. [PMID: 31795192 DOI: 10.3390/ijms20235999] [Cited by in Crossref: 26] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
21 Miller JJ, Blanchet A, Orvain C, Nouchikian L, Reviriot Y, Clarke RM, Martelino D, Wilson D, Gaiddon C, Storr T. Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chem Sci 2019;10:10802-14. [PMID: 32055386 DOI: 10.1039/c9sc04151f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
22 Ortiz GJ, Lozano G. SNPing away at mutant p53 activities. Genes Dev 2018;32:195-6. [PMID: 29491132 DOI: 10.1101/gad.312934.118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci 2019;15:1429-39. [PMID: 31337973 DOI: 10.7150/ijbs.34613] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
24 Gomes S, Raimundo L, Soares J, Loureiro JB, Leão M, Ramos H, Monteiro MN, Lemos A, Moreira J, Pinto M, Chlapek P, Veselska R, Sousa E, Saraiva L. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. Cancer Lett 2019;446:90-102. [PMID: 30664963 DOI: 10.1016/j.canlet.2019.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
25 Gulve N, Prusty BK, Rudel T. Chlamydia trachomatis impairs host base excision repair by downregulating polymerase β. Cell Microbiol 2019;21:e12986. [PMID: 30471195 DOI: 10.1111/cmi.12986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel) 2018;11:E4. [PMID: 30577483 DOI: 10.3390/cancers11010004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
27 Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L. Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer (Dove Med Press) 2018;10:101-12. [PMID: 29950894 DOI: 10.2147/BCTT.S145826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Stiewe T, Haran TE. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat 2018;38:27-43. [PMID: 29857816 DOI: 10.1016/j.drup.2018.05.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 56] [Article Influence: 11.3] [Reference Citation Analysis]
29 Čechová J, Coufal J, Jagelská EB, Fojta M, Brázda V. p73, like its p53 homolog, shows preference for inverted repeats forming cruciforms. PLoS One 2018;13:e0195835. [PMID: 29668749 DOI: 10.1371/journal.pone.0195835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Carrera-Lasfuentes P, Lanas A, Bujanda L, Strunk M, Quintero E, Santolaria S, Benito R, Sopeña F, Piazuelo E, Thomson C, Pérez-Aisa A, Nicolás-Pérez D, Hijona E, Espinel J, Campo R, Manzano M, Geijo F, Pellise M, Zaballa M, González-Huix F, Espinós J, Titó L, Barranco L, D'Amato M, García-González MA. Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. Oncotarget 2017;8:35848-62. [PMID: 28415781 DOI: 10.18632/oncotarget.16261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
31 Tanaka T, Watanabe M, Yamashita K. Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget 2018;9:16234-47. [PMID: 29662640 DOI: 10.18632/oncotarget.24611] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
32 Basu S, Gnanapradeepan K, Barnoud T, Kung CP, Tavecchio M, Scott J, Watters A, Chen Q, Kossenkov AV, Murphy ME. Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. Genes Dev 2018;32:230-43. [PMID: 29463573 DOI: 10.1101/gad.309062.117] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
33 Gingerich MA, Smith JD, Michmerhuizen NL, Ludwig M, Devenport S, Matovina C, Brenner C, Chinn SB. Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients. Head Neck 2018;40:943-54. [PMID: 29427520 DOI: 10.1002/hed.25057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
34 Uno M, Oba-shinjo S, Wakamatsu A, Huang N, Alves VAF, Rosemberg S, de Aguiar PP, Leite C, Miura F, Junior RM, Scaff M, Nagahashi-marie S. Association of TP53 Mutation, p53 Overexpression, and p53 Codon 72 Polymorphism with Susceptibility to Apoptosis in Adult Patients with Diffuse Astrocytomas. Int J Biol Markers 2006;21:50-7. [DOI: 10.1177/172460080602100108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Zhang A, Shi TY, Zhao Y, Xiang J, Yu D, Liang Z, Xu C, Zhang Q, Hu Y, Wang D, He J, Duan P. No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects. Oncotarget 2017;8:112761-9. [PMID: 29348863 DOI: 10.18632/oncotarget.22603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 2018;25:161-8. [PMID: 29099488 DOI: 10.1038/cdd.2017.185] [Cited by in Crossref: 123] [Cited by in F6Publishing: 147] [Article Influence: 24.6] [Reference Citation Analysis]
37 Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. Trends Pharmacol Sci 2017;38:908-27. [PMID: 28818333 DOI: 10.1016/j.tips.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
38 Lv T, Wu X, Sun L, Hu Q, Wan Y, Wang L, Zhao Z, Tu X, Xiao ZJ. p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis. Cell Death Dis 2017;8:e2995. [PMID: 28796261 DOI: 10.1038/cddis.2017.376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
39 Ferraiuolo M, Verduci L, Blandino G, Strano S. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. Int J Mol Sci 2017;18:E961. [PMID: 28467351 DOI: 10.3390/ijms18050961] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
40 Chowdhury SR, Reimer A, Sharan M, Kozjak-Pavlovic V, Eulalio A, Prusty BK, Fraunholz M, Karunakaran K, Rudel T. Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission. J Cell Biol 2017;216:1071-89. [PMID: 28330939 DOI: 10.1083/jcb.201608063] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 11.4] [Reference Citation Analysis]
41 Fu W, Zhuo ZJ, Jia W, Zhu J, Zhu SB, Lin ZF, Wang FH, Xia H, He J, Liu GC. Association between TP53 gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population. Onco Targets Ther 2017;10:1149-54. [PMID: 28260929 DOI: 10.2147/OTT.S131014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
42 Pillai RM, Nair SA. Polymorphism of p53 in cancer prognosis. Indian J Med Res 2016;144:314-6. [PMID: 28139528 DOI: 10.4103/0971-5916.198683] [Reference Citation Analysis]
43 Pfister NT, Prives C. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. Cold Spring Harb Perspect Med 2017;7:a026054. [PMID: 27836911 DOI: 10.1101/cshperspect.a026054] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
44 Hainaut P, Pfeifer GP. Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med 2016;6:a026179. [PMID: 27503997 DOI: 10.1101/cshperspect.a026179] [Cited by in Crossref: 87] [Cited by in F6Publishing: 103] [Article Influence: 14.5] [Reference Citation Analysis]
45 Rodríguez C, Sobrino T, Agulla J, Bobo-Jiménez V, Ramos-Araque ME, Duarte JJ, Gómez-Sánchez JC, Bolaños JP, Castillo J, Almeida Á. Neovascularization and functional recovery after intracerebral hemorrhage is conditioned by the Tp53 Arg72Pro single-nucleotide polymorphism. Cell Death Differ 2017;24:144-54. [PMID: 27768124 DOI: 10.1038/cdd.2016.109] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
46 Guimaraes TA, Farias LC, Fraga CA, Feltenberger JD, Melo GA, Coletta RD, Souza Santos SH, de Paula AM, Guimaraes AL. Evaluation of the antineoplastic activity of gallic acid in oral squamous cell carcinoma under hypoxic conditions. Anticancer Drugs 2016;27:407-16. [PMID: 26849170 DOI: 10.1097/CAD.0000000000000342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
47 Salgado CM, Basu D, Nikiforova M, Hamilton RL, Gehris R, Jakacki R, Panigrahy A, Yatsenko S, Reyes-Múgica M. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis. Melanoma Res 2015;25:453-60. [PMID: 26266759 DOI: 10.1097/CMR.0000000000000188] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
48 Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up. Int J Biol Markers 2016;31:e183-92. [PMID: 26916894 DOI: 10.5301/jbm.5000192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
49 Basu S, Murphy ME. Genetic Modifiers of the p53 Pathway. Cold Spring Harb Perspect Med 2016;6:a026302. [PMID: 27037420 DOI: 10.1101/cshperspect.a026302] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
50 Ferraiuolo M, Di Agostino S, Blandino G, Strano S. Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Front Oncol. 2016;6:77. [PMID: 27066457 DOI: 10.3389/fonc.2016.00077] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
51 Haupt S, Raghu D, Haupt Y. Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. Front Oncol 2016;6:12. [PMID: 26858938 DOI: 10.3389/fonc.2016.00012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
52 Litviakov NV, Freidin MB, Sazonov AE, Khalyuzova MV, Buldakov MA, Karbyshev MS, Albakh ЕN, Isubakova DS, Gagarin АA, Nekrasov GB, Mironova EB, Izosimov АS, Takhauov RM, Karpov АB. Different patterns of allelic imbalance in sporadic tumors and tumors associated with long-term exposure to gamma-radiation. Mutat Res Genet Toxicol Environ Mutagen 2015;794:8-16. [PMID: 26653978 DOI: 10.1016/j.mrgentox.2015.09.003] [Reference Citation Analysis]
53 Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Front Oncol 2015;5:249. [PMID: 26618142 DOI: 10.3389/fonc.2015.00249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
54 Volodko N, Salla M, Eksteen B, Fedorak RN, Huynh HQ, Baksh S. TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World J Gastroenterol 2015; 21(36): 10358-10366 [PMID: 26420962 DOI: 10.3748/wjg.v21.i36.10358] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
55 Zahary MN, Ahmad Aizat AA, Kaur G, Yeong Yeh L, Mazuwin M, Ankathil R. Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population. Oncol Lett 2015;10:3216-22. [PMID: 26722315 DOI: 10.3892/ol.2015.3728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
56 Summerer I, Hess J, Pitea A, Unger K, Hieber L, Selmansberger M, Lauber K, Zitzelsberger H. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells. BMC Genomics 2015;16:654. [PMID: 26328888 DOI: 10.1186/s12864-015-1865-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Puerta-García E, Cañadas-Garre M, Calleja-Hernández MÁ. Molecular biomarkers in colorectal carcinoma. Pharmacogenomics 2015;16:1189-222. [PMID: 26237292 DOI: 10.2217/PGS.15.63] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
58 Pinheiro UB, de Carvalho Fraga CA, Mendes DC, Farias LC, Cardoso CM, Silveira CM, D̕angelo MFSV, Jones KM, Santos SHS, de Paula AMB, Guimarães ALS. Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses. Tumor Biol 2015;36:9259-65. [DOI: 10.1007/s13277-015-3677-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, Haupt S, Pochampally R, Boss GR, Romero DG, Radu CG, Martinez LA. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun 2015;6:7389. [PMID: 26067754 DOI: 10.1038/ncomms8389] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 10.0] [Reference Citation Analysis]
60 Wang G, Fersht AR. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding. Proc Natl Acad Sci U S A 2015;112:2443-8. [PMID: 25675527 DOI: 10.1073/pnas.1500262112] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
61 Adduri RS, Katamoni R, Pandilla R, Madana SN, Paripati AK, Kotapalli V, Bashyam MD. TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India. PLoS One 2014;9:e114002. [PMID: 25436609 DOI: 10.1371/journal.pone.0114002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hao Q, Cho WC. Battle against cancer: an everlasting saga of p53. Int J Mol Sci 2014;15:22109-27. [PMID: 25470027 DOI: 10.3390/ijms151222109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
63 Trietsch MD, Nooij LS, Gaarenstroom KN, van Poelgeest MI. Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature. Gynecol Oncol 2015;136:143-57. [PMID: 25448458 DOI: 10.1016/j.ygyno.2014.11.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
64 Sina M, Pedram M, Ghojazadeh M, Kochaki A, Aghbali A. P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran. Med Oral Patol Oral Cir Bucal 2014;19:e550-5. [PMID: 24880450 DOI: 10.4317/medoral.19794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
65 Nobusawa A, Sano T, Yokoo S, Oyama T. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014;118:e146-50. [DOI: 10.1016/j.oooo.2014.03.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
66 Siegl C, Prusty BK, Karunakaran K, Wischhusen J, Rudel T. Tumor suppressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection. Cell Rep 2014;9:918-29. [PMID: 25437549 DOI: 10.1016/j.celrep.2014.10.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
67 Chakrobarty B, Roy JG, Majumdar S, Uppala D. Relationship among tobacco habits, human papilloma virus (HPV) infection, p53 polymorphism/mutation and the risk of oral squamous cell carcinoma. J Oral Maxillofac Pathol 2014;18:211-6. [PMID: 25328301 DOI: 10.4103/0973-029X.140752] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
68 Costanzo A, Pediconi N, Narcisi A, Guerrieri F, Belloni L, Fausti F, Botti E, Levrero M. TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. FEBS Lett 2014;588:2590-9. [PMID: 24983500 DOI: 10.1016/j.febslet.2014.06.047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
69 Deng X, Cheng Y, Yang X, Li S, Zhao R, Liu K, Liu J, Cao Q, Qin C, Shao P, Meng X, Li J, Lu Q, Yin C. Meta-analysis reveals a lack of association between UGT2B17 deletion polymorphism and tumor susceptibility. PLoS One 2014;9:e96812. [PMID: 24802609 DOI: 10.1371/journal.pone.0096812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
70 Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, Lee C, Varanasi L, Yang Y, Martinez LA, Luo J, Ambs S, Sharma S, Wakefield LM, Meltzer PS, Lal A. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene 2015;34:1094-104. [PMID: 24662829 DOI: 10.1038/onc.2014.46] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
71 Hartwig FP, Entiauspe LG, Nunes EM, Rodrigues FM, Collares T, Seixas FK, da Silveira MF. Evidence for an epistatic effect between TP53 R72P and MDM2 T309G SNPs in HIV infection: a cross-sectional study in women from South Brazil. PLoS One 2014;9:e89489. [PMID: 24586820 DOI: 10.1371/journal.pone.0089489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
72 Eskander EF, Abd-Rabou AA, Yahya SM, El Sherbini A, Mohamed MS, Shaker OG. "P53 codon 72 single base substitution in viral hepatitis C and hepatocarcinoma incidences". Indian J Clin Biochem 2014;29:3-7. [PMID: 24478542 DOI: 10.1007/s12291-013-0317-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci 2013;14:19257-75. [PMID: 24065105 DOI: 10.3390/ijms140919257] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.8] [Reference Citation Analysis]
74 Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013;177:1317-25. [PMID: 23729685 DOI: 10.1093/aje/kws394] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
75 Rao GH, Liu HM, Li BW, Hao JJ, Yang YL, Wang MR, Wang XH, Wang J, Jin HJ, Du L, Chen Q. Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. Acta Pharmacol Sin 2013;34:793-804. [PMID: 23736004 DOI: 10.1038/aps.2013.56] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
76 Yang X, Yang B, Liu Y, Xu S, Li B. The association between TP53 Arg72pro polymorphism and non-melanoma skin cancer risk: a meta-analysis including 7,107 subjects. Indian J Dermatol 2013;58:175-80. [PMID: 23723465 DOI: 10.4103/0019-5154.110823] [Reference Citation Analysis]
77 Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114. [PMID: 23717813 DOI: 10.3389/fonc.2013.00114] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 7.6] [Reference Citation Analysis]
78 Xie X, Wang H, Jin H, Ouyang S, Zhou J, Hu J, Xi X, Luo J, Zhang Y, Hu B. Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat Oncol 2013;8:117. [PMID: 23663243 DOI: 10.1186/1748-717X-8-117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
79 Chen F, Ou-yang F, Yang S, Tsai E, Hou M. p53 codon 72 polymorphism in Taiwanese breast cancer patients. The Kaohsiung Journal of Medical Sciences 2013;29:259-64. [DOI: 10.1016/j.kjms.2012.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
80 Pellicciotta I, Yang CP, Venditti CA, Goldberg GL, Shahabi S. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int 2013;13:33. [PMID: 23574945 DOI: 10.1186/1475-2867-13-33] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
81 Zhang L, Shao N, Yu Q, Hua L, Mi Y, Feng N. Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis. J Biomed Res 2011;25:25-32. [PMID: 23554668 DOI: 10.1016/S1674-8301(11)60003-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
82 Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013;20:898-909. [PMID: 23538418 DOI: 10.1038/cdd.2013.17] [Cited by in Crossref: 151] [Cited by in F6Publishing: 167] [Article Influence: 16.8] [Reference Citation Analysis]
83 Malisic E, Jankovic R, Brotto K, Radulovic S. TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. Arch Gynecol Obstet 2013;288:621-5. [PMID: 23483183 DOI: 10.1007/s00404-013-2783-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
84 Lajin B, Alhaj Sakur A, Alachkar A. Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Res Treat 2013;138:611-9. [PMID: 23468244 DOI: 10.1007/s10549-013-2467-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
85 Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol 2013;34:1301-15. [DOI: 10.1007/s13277-013-0692-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
86 Tilak AR, Kumar S, Pant MC, Mathur N, Kumar A. Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a North Indian population. DNA Cell Biol 2013;32:66-72. [PMID: 23317414 DOI: 10.1089/dna.2012.1792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
87 Malisic EJ, Jankovic RN, Jakovljevic KV, Radulovic SS. Association of TP53 codon 72 polymorphism with susceptibility to ovarian carcinomas in Serbian women. European Journal of Obstetrics & Gynecology and Reproductive Biology 2013;166:90-3. [DOI: 10.1016/j.ejogrb.2012.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
88 Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 2013;119:1013-22. [PMID: 23165797 DOI: 10.1002/cncr.27837] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
89 Duldulao MP, Lee W, Nelson RA, Ho J, Le M, Chen Z, Li W, Kim J, Garcia-Aguilar J. Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer 2013;119:1106-12. [PMID: 23096768 DOI: 10.1002/cncr.27862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
90 Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268-1286. [PMID: 22713868 DOI: 10.1101/gad.190678.112] [Cited by in Crossref: 721] [Cited by in F6Publishing: 733] [Article Influence: 72.1] [Reference Citation Analysis]
91 Roshan A, Jones PH. Chronic low dose UV exposure and p53 mutation: tilting the odds in early epidermal preneoplasia? Int J Radiat Biol 2012;88:682-7. [PMID: 22671441 DOI: 10.3109/09553002.2012.699697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
92 Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncology 2012;48:602-7. [DOI: 10.1016/j.oraloncology.2012.01.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
93 Yang SY, Yang TY, Li YJ, Chen KC, Liao KM, Hsu KH, Tsai CR, Chen CY, Hsu CP, Hsia JY, Chuang CY, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Hsiung CA, Shen CY, Chang GC, Yang PC, Chen CJ. EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. Int J Cancer 2013;132:449-58. [PMID: 22573488 DOI: 10.1002/ijc.27630] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
94 Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, Li R, Martinez LA. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 2012;26:830-45. [PMID: 22508727 DOI: 10.1101/gad.181685.111] [Cited by in Crossref: 126] [Cited by in F6Publishing: 129] [Article Influence: 12.6] [Reference Citation Analysis]
95 Altilia S, Santoro A, Malagoli D, Lanzarini C, Ballesteros Álvarez JA, Galazzo G, Porter DC, Crocco P, Rose G, Passarino G, Roninson IB, Franceschi C, Salvioli S. TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging (Albany NY) 2012;4:28-39. [PMID: 22289634 DOI: 10.18632/aging.100425] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
96 Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis 2012;27:211-8. [PMID: 22294769 DOI: 10.1093/mutage/ger067] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
97 Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, Orlow I. Investigation of the Effect of MDM2 SNP309 and TP53 Arg72Pro Polymorphisms on the Age of Onset of Cutaneous Melanoma. Journal of Investigative Dermatology 2012;132:1471-8. [DOI: 10.1038/jid.2012.15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
98 Loeb KR, Asgari MM, Hawes SE, Feng Q, Stern JE, Jiang M, Argenyi ZB, de Villiers EM, Kiviat NB. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One 2012;7:e34422. [PMID: 22545084 DOI: 10.1371/journal.pone.0034422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
99 Marioni G, Agostini M, Bedin C, Blandamura S, Stellini E, Favero G, Lionello M, Giacomelli L, Burti S, D’angelo E, Nitti D, Staffieri A, De Filippis C. Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants: Survivin and laryngeal SCC prognosis. Histopathology 2012;61:247-56. [DOI: 10.1111/j.1365-2559.2012.04217.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
100 Engin AB, Karahalil B, Karakaya AE, Engin A. Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol. 2011;62:207-214. [PMID: 21971103 DOI: 10.2478/10004-1254-62-2011-2098] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
101 Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, Siddiqi MA. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol 2012;33:927-33. [PMID: 22249977 DOI: 10.1007/s13277-012-0318-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
102 Coschi CH, Dick FA. Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci 2012;69:2009-24. [PMID: 22223110 DOI: 10.1007/s00018-011-0910-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
103 Arning L, Epplen JT. Genetic modifiers of Huntington’s disease: beyond CAG. Future Neurology 2012;7:93-109. [DOI: 10.2217/fnl.11.65] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
104 Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW. p73 in Cancer. Genes Cancer. 2011;2:491-502. [PMID: 21779517 DOI: 10.1177/1947601911408890] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 9.4] [Reference Citation Analysis]
105 Bisso A, Collavin L, Del Sal G. p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 2011;17:578-90. [PMID: 21391908 DOI: 10.2174/138161211795222667] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
106 Cheng J, Norstrand DW, Medeiros-Domingo A, Tester DJ, Valdivia CR, Tan BH, Vatta M, Makielski JC, Ackerman MJ. LQTS-associated mutation A257G in α1-syntrophin interacts with the intragenic variant P74L to modify its biophysical phenotype. Cardiogenetics 2011;1:136. [PMID: 24319568 DOI: 10.4081/cardiogenetics.2011.e13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
107 Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 2011;31:4464-81. [PMID: 21930790 DOI: 10.1128/MCB.05574-11] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
108 Maas AM, Bretz AC, Mack E, Stiewe T. Targeting p73 in cancer. Cancer Lett 2013;332:229-36. [PMID: 21903324 DOI: 10.1016/j.canlet.2011.07.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
109 Denisov EV, Sukhanovskaya TV, Dultseva TS, Malinovskaya EA, Litviakov NV, Slonimskaya EM, Choinzonov EL, Cherdyntseva NV. Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations. Genet Test Mol Biomarkers 2011;15:901-7. [PMID: 21810023 DOI: 10.1089/gtmb.2011.0038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
110 Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics 2008;9:200-7. [PMID: 19440517 DOI: 10.2174/138920208784340713] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
111 Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep 2012;39:1731-8. [PMID: 21617940 DOI: 10.1007/s11033-011-0913-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
112 Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol 2011;38:215-24. [PMID: 21421111 DOI: 10.1053/j.seminoncol.2011.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
113 Frank AK, Pietsch EC, Dumont P, Tao J, Murphy ME. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol Ther 2011;11:740-5. [PMID: 21307660 DOI: 10.4161/cbt.11.8.14906] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
114 Bug M, Dobbelstein M. Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. Oncogene 2011;30:3612-24. [DOI: 10.1038/onc.2011.72] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
115 Santi R, Cetica V, Franchi A, Pepi M, Cesinaro AM, Miracco C, Paglierani M, De Giorgi V, Delfino C, Difonzo EM, Pimpinelli N, Bianchi S, Sardi I, Santucci M, Massi D. Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy. Histopathology 2011;58:455-66. [PMID: 21323968 DOI: 10.1111/j.1365-2559.2011.03770.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
116 Liu W, He L, Ramírez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 2011;71:2423-7. [PMID: 21292812 DOI: 10.1158/0008-5472.CAN-10-2689] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
117 Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jørgensen T, Sandbæk A, Lauritzen T, Madsbad S, Hansen T, Pedersen O; DIAGRAM Consortium. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One 2011;6:e15813. [PMID: 21283750 DOI: 10.1371/journal.pone.0015813] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
118 Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2011;129:920-930. [PMID: 20886596 DOI: 10.1002/ijc.25710] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
119 Pandith AA, Shah ZA, Khan NP, Rasool R, Afroze D, Yousuf A, Wani S, Siddiqi M. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genetics and Cytogenetics 2010;203:263-8. [DOI: 10.1016/j.cancergencyto.2010.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
120 Almquist LM, Karagas MR, Christensen BC, Welsh MM, Perry AE, Storm CA, Nelson HH. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis 2011;32:327-30. [PMID: 21123835 DOI: 10.1093/carcin/bgq256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
121 Chung WH, Dao RL, Chen LK, Hung SI. The role of genetic variants in human longevity. Ageing Res Rev 2010;9 Suppl 1:S67-78. [PMID: 20708717 DOI: 10.1016/j.arr.2010.08.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
122 Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011;223:116-26. [PMID: 21125670 DOI: 10.1002/path.2784] [Cited by in Crossref: 239] [Cited by in F6Publishing: 251] [Article Influence: 19.9] [Reference Citation Analysis]
123 Ueda M, Toji E, Nunobiki O, Sato N, Izuma S, Torii K, Okamoto Y, Noda S. Germline polymorphisms of glutathione-S-transferase GSTM1, GSTT1 and p53 codon 72 in cervical carcinogenesis. Hum Cell 2010;23:119-25. [PMID: 21166882 DOI: 10.1111/j.1749-0774.2010.00089.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
124 Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008. [PMID: 20182602 DOI: 10.1101/cshperspect.a001008] [Cited by in Crossref: 847] [Cited by in F6Publishing: 944] [Article Influence: 70.6] [Reference Citation Analysis]
125 Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010;2:a001107. [PMID: 20182618 DOI: 10.1101/cshperspect.a001107] [Cited by in Crossref: 431] [Cited by in F6Publishing: 472] [Article Influence: 35.9] [Reference Citation Analysis]
126 Jiang DK, Wang WZ, Ren WH, Yao L, Peng B, Yu L. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. J Invest Dermatol. 2011;131:220-228. [PMID: 20861852 DOI: 10.1038/jid.2010.270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
127 Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A. Association of P53 codon 72 polymorphism and ameloblastoma: P53 codon 72 polymorphism in ameloblastoma. Oral Diseases 2010;16:631-5. [DOI: 10.1111/j.1601-0825.2010.01664.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
128 Zhu F, Dollé ME, Berton TR, Kuiper RV, Capps C, Espejo A, McArthur MJ, Bedford MT, van Steeg H, de Vries A, Johnson DG. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 2010;70:5851-9. [PMID: 20587514 DOI: 10.1158/0008-5472.CAN-09-4646] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
129 Wolter J, Angelini P, Irwin M. p53 family: Therapeutic targets in neuroblastoma. Future Oncol 2010;6:429-44. [PMID: 20222799 DOI: 10.2217/fon.09.176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
130 Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis. 2010;31:1475-1482. [PMID: 20538734 DOI: 10.1093/carcin/bgq118] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
131 Kucab JE, Phillips DH, Arlt VM. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model: Cancer aetiology and TP53 mutations. FEBS Journal 2010;277:2567-83. [DOI: 10.1111/j.1742-4658.2010.07676.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
132 Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36:431-438. [PMID: 20363586 DOI: 10.1016/j.ejso.2010.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
133 Eren F, Akkiprik M, Atuğ O, Sönmez O, Tahan G, Ozdemir F, Hamzaoğlu HO, Celikel CA, Imeryüz N, Avşar E, Ozer A. R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. Pathol Oncol Res 2010;16:563-8. [PMID: 20309662 DOI: 10.1007/s12253-010-9255-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
134 Tominaga T, Iwahashi M, Takifuji K, Hotta T, Yokoyama S, Matsuda K, Higashiguchi T, Oku Y, Nasu T, Yamaue H. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Int J Cancer 2010;126:1691-701. [PMID: 19810096 DOI: 10.1002/ijc.24929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
135 Zhu KX, Li YM, Li X, Zhou WC, Shan Y, Liu T, He WT. Association of P53 Arg72Pro polymorphism and Helicobacter pylori infection with risk of gastric cancer in a high incidence area in China. Shijie Huaren Xiaohua Zazhi 2009; 17(36): 3734-3739 [DOI: 10.11569/wcjd.v17.i36.3734] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Grochola LF, Zeron-Medina J, Mériaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010;2:a001032. [PMID: 20452958 DOI: 10.1101/cshperspect.a001032] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 4.4] [Reference Citation Analysis]
137 Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Miyagi Y. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 2009;9:420. [PMID: 19954513 DOI: 10.1186/1471-2407-9-420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
138 Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 2009;125:2903-11. [PMID: 19623649 DOI: 10.1002/ijc.24603] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
139 Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009;15:2406-16. [PMID: 19339276 DOI: 10.1158/1078-0432.CCR-08-1719] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
140 Belyi VA, Levine AJ. One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci U S A 2009;106:17609-10. [PMID: 19826090 DOI: 10.1073/pnas.0910634106] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
141 Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer 2009;101:1606-12. [PMID: 19773755 DOI: 10.1038/sj.bjc.6605335] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 8.4] [Reference Citation Analysis]
142 Sobti RC, Kaur P, Kaur S, Janmeja AK, Jindal SK, Kishan J, Raimondi S. Impact of interaction of polymorphic forms of p53 codon 72 and N-acetylation gene (NAT2) on the risk of lung cancer in the North Indian population. DNA Cell Biol 2009;28:443-9. [PMID: 19558213 DOI: 10.1089/dna.2008.0797] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
143 Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 2009;48:790-800. [PMID: 19204927 DOI: 10.1002/mc.20523] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
144 Shinohara A, Sakano S, Hinoda Y, Nishijima J, Kawai Y, Misumi T, Nagao K, Hara T, Matsuyama H. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci 2009;100:2376-82. [PMID: 19764997 DOI: 10.1111/j.1349-7006.2009.01331.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
145 Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13:440-453. [PMID: 19379143 DOI: 10.1111/j.1582-4934.2008.00634.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
146 Hishida A, Matsuo K, Tajima K, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Naoe T, Hamajima N. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at Exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's Lymphoma in Japanese. Leukemia & Lymphoma 2009;45:957-64. [DOI: 10.1080/10428190310001638878] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
147 Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das B, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y, Pegoraro R, Pillai M, Ranzani G, Rezza G, Rosenthal AN, Roychoudhury S, Saranath D, Schmitt VM, Sengupta S, Settheetham-ishida W, Shirasawa H, Snijders PJ, Stoler MH, Suárez-rincón AE, Szarka K, Tachezy R, Ueda M, van der Zee AG, von Knebel Doeberitz M, Wu M, Yamashita T, Zehbe I, Blettner M. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. The Lancet Oncology 2009;10:772-84. [DOI: 10.1016/s1470-2045(09)70187-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 7.9] [Reference Citation Analysis]
148 Sreeja L, Syamala V, Raveendran PB, Santhi S, Madhavan J, Ankathil R. p53 Arg72Pro Polymorphism Predicts Survival Outcome in Lung Cancer Patients in Indian Population. Cancer Investigation 2009;26:41-6. [DOI: 10.1080/07357900701638459] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
149 Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis. 2009;14:336-347. [PMID: 19229632 DOI: 10.1007/s10495-009-0327-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
150 Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu GS. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008;9:847-52. [PMID: 18988302 DOI: 10.1631/jzus.B0820100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
151 Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107. [PMID: 19165225 DOI: 10.1038/nrc2584] [Cited by in Crossref: 427] [Cited by in F6Publishing: 412] [Article Influence: 32.8] [Reference Citation Analysis]
152 Ueda M, Toji E, Nunobiki O, Izuma S, Okamoto Y, Torii K, Noda S. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum Cell 2008;21:95-104. [PMID: 19067761 DOI: 10.1111/j.1749-0774.2008.00058.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
153 Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 2009;113:109-14. [PMID: 19193430 DOI: 10.1016/j.ygyno.2008.12.036] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
154 Imyanitov EN. Use of elderly tumor-free subjects as a “supercontrol” for cancer epidemiological studies: pros and cons. Mechanisms of Ageing and Development 2009;130:122-7. [DOI: 10.1016/j.mad.2008.03.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
155 Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-87. [PMID: 19043449 DOI: 10.1038/nrd2656] [Cited by in Crossref: 438] [Cited by in F6Publishing: 433] [Article Influence: 31.3] [Reference Citation Analysis]
156 Zemleduch T, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodziński PP. Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. Oral Oncol 2009;45:683-6. [PMID: 19091625 DOI: 10.1016/j.oraloncology.2008.10.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
157 Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A, Ozer A. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Pathol Oncol Res 2009;15:359-68. [DOI: 10.1007/s12253-008-9129-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
158 Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008;27:6507-21. [PMID: 18955976 DOI: 10.1038/onc.2008.315] [Cited by in Crossref: 192] [Cited by in F6Publishing: 183] [Article Influence: 13.7] [Reference Citation Analysis]
159 Chang Z, Guo CL, Ahronowitz I, Stemmer-Rachamimov AO, MacCollin M, Nunes FP. A role for the p53 pathway in the pathology of meningiomas with NF2 loss. J Neurooncol 2009;91:265-70. [PMID: 18974932 DOI: 10.1007/s11060-008-9721-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
160 Wegman PP, Marcus NJ, Malakkaran BP, Wingren S. Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat 2009;118:15-20. [PMID: 18853251 DOI: 10.1007/s10549-008-0212-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
161 Yarosh DB, Peña A, Brown DA. DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel. Biomarkers 2008;10:188-202. [DOI: 10.1080/13547500500138732] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
162 Hamaguchi M, Nishio M, Toyama T, Sugiura H, Kondo N, Fujii Y, Yamashita H. Possible Difference in Frequencies of Genetic Polymorphisms of Estrogen Receptor  , Estrogen Metabolism and P53 Genes Between Estrogen Receptor-positive and -negative Breast Cancers. Japanese Journal of Clinical Oncology 2008;38:734-42. [DOI: 10.1093/jjco/hyn097] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
163 Han J, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807. [DOI: 10.1002/cncr.23668] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
164 Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, Xie Y. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 2008;122:2761-6. [PMID: 18348141 DOI: 10.1002/ijc.23454] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
165 Nordgard SH, Alnaes GI, Hihn B, Lingjaerde OC, Liestøl K, Tsalenko A, Sørlie T, Lønning PE, Børresen-Dale AL, Kristensen VN. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 2008;123:577-85. [PMID: 18498133 DOI: 10.1002/ijc.23541] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
166 Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M, Nitti D. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 2009;35:415-9. [PMID: 18468835 DOI: 10.1016/j.ejso.2008.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
167 Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol 2009;19:188-94. [PMID: 18462472 DOI: 10.1111/j.1750-3639.2008.00170.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
168 Tu H, Chen H, Kao S, Lin S, Liu C, Chang K. MDM2 SNP 309 and codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiotherapy and Oncology 2008;87:243-52. [DOI: 10.1016/j.radonc.2008.03.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
169 Chumakov PM. Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) 2007;72:1399-421. [PMID: 18282133 DOI: 10.1134/s0006297907130019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
170 Jänicke RU, Sohn D, Schulze-osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008;15:959-76. [DOI: 10.1038/cdd.2008.33] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 9.8] [Reference Citation Analysis]
171 Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008;20:90-6. [PMID: 18043262 DOI: 10.1097/CCO.0b013e3282f31d6f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
172 Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, Wei Q, Li G. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis 2008;29:875-9. [PMID: 18258602 DOI: 10.1093/carcin/bgn039] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
173 Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A, Stiewe T. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 2008;27:792-803. [PMID: 18239687 DOI: 10.1038/emboj.2008.13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
174 Ichwan SJA, Ikeda M. Defect in Ser46 Phosphorylation of p53 Protein : A Resistance Mechanism against p53 Gene Transfer in Oral Squamous Cell Carcinoma Cells. Journal of Oral Biosciences 2008;50:98-106. [DOI: 10.1016/s1349-0079(08)80023-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Spitsina EV, Yakunina NY, Chudakova DA, Nikitin AG, Svetlova GN, Soluyanova TN, Strokov IA, Nosikov VV. The association of the TP53 polymorphisms Pro72Arg and C(−594)CC with diabetic polyneuropathy in Russian Muscovites with type 1 diabetes mellitus. Mol Biol 2007;41:901-5. [DOI: 10.1134/s0026893307060052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
176 Partridge M, Costea D, Huang X. The changing face of p53 in head and neck cancer. International Journal of Oral and Maxillofacial Surgery 2007;36:1123-38. [DOI: 10.1016/j.ijom.2007.06.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
177 Bhattacharya P, Sengupta S. Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens 2007;70:283-93. [PMID: 17767549 DOI: 10.1111/j.1399-0039.2007.00894.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
178 Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007;12:303-12. [PMID: 17936556 DOI: 10.1016/j.ccr.2007.10.001] [Cited by in Crossref: 240] [Cited by in F6Publishing: 224] [Article Influence: 16.0] [Reference Citation Analysis]
179 Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008;27:2788-94. [PMID: 17998932 DOI: 10.1038/sj.onc.1210932] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
180 Siriwardena BS, Tilakaratne A, Amaratunga EA, Udagama MN, Ogawa I, Kudo Y, Takata T, Tilakaratne WM. Analysis of histopathological and immunohistochemical differences of oral squamous cell carcinoma in young and old patients in Sri Lanka. J Oral Pathol Med 2007;36:357-62. [PMID: 17559498 DOI: 10.1111/j.1600-0714.2007.00548.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
181 Kashima T, Makino K, Soemantri A, Ishida T. TP53 codon 72 polymorphism in 12 populations of insular Southeast Asia and Oceania. J Hum Genet 2007;52:694-7. [DOI: 10.1007/s10038-007-0168-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
182 Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006;13:951-961. [PMID: 16575405 DOI: 10.1038/sj.cdd.4401916] [Cited by in Crossref: 320] [Cited by in F6Publishing: 334] [Article Influence: 21.3] [Reference Citation Analysis]
183 Strano S, Dell'Orso S, Mongiovi AM, Monti O, Lapi E, Di Agostino S, Fontemaggi G, Blandino G. Mutant p53 proteins: between loss and gain of function. Head Neck 2007;29:488-96. [PMID: 17123310 DOI: 10.1002/hed.20531] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
184 Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 2007;204:1295-301. [PMID: 17535973 DOI: 10.1084/jem.20062476] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
185 Yamashita K, Miyazaki M, Yamaguchi Y, Nakamura H, Maeda H. Microfluidic Thermodynamics of the Shift in Thermal Stability of DNA Duplex in a Microchannel Laminar Flow. J Phys Chem B 2007;111:6127-33. [DOI: 10.1021/jp0686745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
186 Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65. [PMID: 17401424 DOI: 10.1038/sj.onc.1210302] [Cited by in Crossref: 563] [Cited by in F6Publishing: 565] [Article Influence: 37.5] [Reference Citation Analysis]
187 Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007;26:2220-5. [PMID: 17401431 DOI: 10.1038/sj.onc.1210311] [Cited by in Crossref: 118] [Cited by in F6Publishing: 122] [Article Influence: 7.9] [Reference Citation Analysis]
188 Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene. 2007;26:2145-2156. [PMID: 17401423 DOI: 10.1038/sj.onc.1210280] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 10.5] [Reference Citation Analysis]
189 Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene. 2007;26:2212-2219. [PMID: 17401430 DOI: 10.1038/sj.onc.1210296] [Cited by in Crossref: 176] [Cited by in F6Publishing: 163] [Article Influence: 11.7] [Reference Citation Analysis]
190 Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V, Ciferri E, Percivale P, Bianchi Scarrà G, Nasti S, Fronza G, Varesco L. Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the <i>p53</i> PIN3 A2-Pro72 Haplotype. Digestion 2007;74:228-35. [DOI: 10.1159/000100966] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
191 Marabese M, Vikhanskaya F, Broggini M. p73: a chiaroscuro gene in cancer. Eur J Cancer 2007;43:1361-72. [PMID: 17428654 DOI: 10.1016/j.ejca.2007.01.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
192 Sansone P, Storci G, Pandolfi S, Montanaro L, Chieco P, Bonafé M. The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer 2007;96:1302-8. [PMID: 17406354 DOI: 10.1038/sj.bjc.6603723] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
193 Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007;26:2243-54. [DOI: 10.1038/sj.onc.1210295] [Cited by in Crossref: 128] [Cited by in F6Publishing: 127] [Article Influence: 8.5] [Reference Citation Analysis]
194 Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007;35:2093-104. [PMID: 17344317 DOI: 10.1093/nar/gkm099] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
195 Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-83. [PMID: 17334395 DOI: 10.1038/sj.onc.1210337] [Cited by in Crossref: 185] [Cited by in F6Publishing: 178] [Article Influence: 12.3] [Reference Citation Analysis]
196 Stefanaki I, Stratigos A, Dimisianos G, Nikolaou V, Papadopoulos O, Polydorou D, Gogas H, Tsoutsos D, Panagiotou P, Kanavakis E, Antoniou C, Katsambas A. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol 2007;156:357-62. [DOI: 10.1111/j.1365-2133.2006.07645.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 265] [Article Influence: 1.7] [Reference Citation Analysis]
197 Bendesky A, Rosales A, Salazar AM, Sordo M, Peniche J, Ostrosky-Wegman P. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res 2007;619:38-44. [PMID: 17403527 DOI: 10.1016/j.mrfmmm.2007.01.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
198 Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007;17:66-70. [PMID: 17208429 DOI: 10.1016/j.gde.2006.12.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
199 Zhang L, Nie L, Maki CG. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer 2006;5:68. [PMID: 17150106 DOI: 10.1186/1476-4598-5-68] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
200 Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Hüttinger-Kirchhof N, Oswald C, Friedl P, Gattenlöhner S, Burek C, Rosenwald A, Stiewe T. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006;10:281-93. [PMID: 17045206 DOI: 10.1016/j.ccr.2006.08.024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 5.1] [Reference Citation Analysis]
201 Phang BH, Sabapathy K. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models. Oncogene 2007;26:2964-74. [DOI: 10.1038/sj.onc.1210112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
202 Mitra S, Banerjee S, Misra C, Singh RK, Roy A, Sengupta A, Panda CK, Roychoudhury S. Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J Clin Pathol. 2007;60:1040-1047. [PMID: 17079356 DOI: 10.1136/jcp.2005.034835] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
203 Yi SY, Lee WJ. A p53 genetic polymorphism of gastric cancer: Difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 2006; 12(40): 6536-6539 [PMID: 17072987 DOI: 10.3748/wjg.v12.i40.6536] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
204 Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 2006;281:34096-103. [PMID: 16980297 DOI: 10.1074/jbc.M603654200] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 4.8] [Reference Citation Analysis]
205 Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, Brachmann RK. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007;28:289-98. [PMID: 16861262 DOI: 10.1093/carcin/bgl132] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
206 Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 2006;132:521-8. [PMID: 16788846 DOI: 10.1007/s00432-006-0099-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
207 Lima JM, Serafim PV, Silva ID, Forones NM. [Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer]. Arq Gastroenterol 2006;43:8-13. [PMID: 16699611 DOI: 10.1590/s0004-28032006000100005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
208 Wegman P, Stal O, Stenmark Askmalm M, Nordenskjöld B, Rutqvist L, Wingren S. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenetics and Genomics 2006;16:347-51. [DOI: 10.1097/01.fpc.0000204997.84182.69] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
209 Fernandez-Garcia B, Vaqué JP, Herreros-Villanueva M, Marques-Garcia F, Castrillo F, Fernandez-Medarde A, León J, Marín MC. p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ 2007;14:254-65. [PMID: 16645632 DOI: 10.1038/sj.cdd.4401945] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
210 Enari M, Ohmori K, Kitabayashi I, Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev 2006;20:1087-99. [PMID: 16618797 DOI: 10.1101/gad.1381906] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
211 Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11. [DOI: 10.1038/sj.onc.1209367] [Cited by in Crossref: 151] [Cited by in F6Publishing: 141] [Article Influence: 9.4] [Reference Citation Analysis]
212 Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9): 1426-1429 [PMID: 16552814 DOI: 10.3748/wjg.v12.i9.1426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
213 Pezeshki A, Sari-aslanl F, Ghaderi A, Doroudchi M. p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res 2006;12:29-33. [DOI: 10.1007/bf02893428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
214 Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006;52:9-14. [PMID: 16499995 DOI: 10.1016/j.lungcan.2005.12.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
215 Kochethu G, Delgado J, Pepper C, Starczynski J, Hooper L, Krishnan S, Fegan C, Pratt G. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res. 2006;30:1113-1118. [PMID: 16458962 DOI: 10.1016/j.leukres.2005.12.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
216 Puente XS, Velasco G, Gutiérrez-Fernández A, Bertranpetit J, King MC, López-Otín C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics. 2006;7:15. [PMID: 16438707 DOI: 10.1186/1471-2164-7-15] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
217 Melino G. p73, the “Assistant” Guardian of the Genome? Annals of the New York Academy of Sciences 2003;1010:9-15. [DOI: 10.1196/annals.1299.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
218 Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R, Murthy NS, Husain SA, Das BC. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 2005;128:3999-4007. [PMID: 16354872 DOI: 10.1378/chest.128.6.3999] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
219 Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-wilde H, Broelsch CE, Deleo AB, Gerken G, Beckebaum S. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int J Cancer 2006;119:2851-60. [DOI: 10.1002/ijc.22251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
220 Twu C, Jiang R, Shu C, Lin J. Association of p53 Codon 72 Polymorphism with Risk of Hypopharyngeal Squamous Cell Carcinoma in Taiwan. Journal of the Formosan Medical Association 2006;105:99-104. [DOI: 10.1016/s0929-6646(09)60330-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
221 Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecologic Oncology 2006;100:173-8. [DOI: 10.1016/j.ygyno.2005.08.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
222 Lee JM, Shun CT, Wu MT, Chen YY, Yang SY, Hung HI, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee YC. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 2006;594:181-8. [PMID: 16318864 DOI: 10.1016/j.mrfmmm.2005.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
223 Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q, Shen H. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006;27:766-71. [DOI: 10.1093/carcin/bgi295] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
224 Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Science 2005;96:729-37. [DOI: 10.1111/j.1349-7006.2005.00116.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 5.2] [Reference Citation Analysis]
225 Kamiya Y, Ohshima T. The Individual Cell Properties of Oral Squamous Cell Carcinoma and p53 Tumor Suppressor Gene Mutation. Oral Science International 2005;2:104-17. [DOI: 10.1016/s1348-8643(05)80013-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
226 Ichwan SJA, Yamada S, Sumrejkanchanakij P, Ibrahim-auerkari E, Eto K, Ikeda M. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 2006;25:1216-24. [DOI: 10.1038/sj.onc.1209158] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
227 Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther 2005;315:1403-11. [PMID: 16169939 DOI: 10.1124/jpet.105.089342] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 6.6] [Reference Citation Analysis]
228 Saffari B, Bernstein L, Hong D, Sullivan-halley J, Runnebaum I, Grill H, Jones L, El-naggar A, Press M. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005;15:952-63. [DOI: 10.1111/j.1525-1438.2005.00159.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
229 Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 2005;5:105. [PMID: 16109171 DOI: 10.1186/1471-2407-5-105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
230 Gwosdz C, Scheckenbach K, Lieven O, Reifenberger J, Knopf A, Bier H, Balz V. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 2006;118:577-82. [DOI: 10.1002/ijc.21366] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
231 Yamashita K, Ogura D, Yamaguchi Y, Miyazaki M, Briones MP, Nakamura H, Maeda H. Specific molecule localization in microchannel laminar flow and its application for non-immobilized-probe analysis. Anal Bioanal Chem 2005;382:1477-83. [DOI: 10.1007/s00216-005-3368-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
232 Wang XL, Wang J. Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis. World J Surg 2005;29:344-53. [PMID: 15696395 DOI: 10.1007/s00268-004-7819-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
233 Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834-42. [PMID: 15865939 DOI: 10.1016/j.bbrc.2005.03.190] [Cited by in Crossref: 184] [Cited by in F6Publishing: 165] [Article Influence: 10.8] [Reference Citation Analysis]
234 Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005;222:57-65. [PMID: 15837541 DOI: 10.1016/j.canlet.2004.11.025] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 4.2] [Reference Citation Analysis]
235 Dulloo I, Sabapathy K. Transactivation-dependent and -independent regulation of p73 stability. J Biol Chem 2005;280:28203-14. [PMID: 15919663 DOI: 10.1074/jbc.M501702200] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
236 Jaworski M, Hailfinger S, Buchmann A, Hergenhahn M, Hollstein M, Ittrich C, Schwarz M. Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 2005;26:1829-34. [PMID: 15917304 DOI: 10.1093/carcin/bgi142] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
237 Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005;26:1770-3. [DOI: 10.1093/carcin/bgi125] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
238 Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529-535. [PMID: 15548361 DOI: 10.1593/neo.04178] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
239 Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 2005;137:98-103. [PMID: 15950766 DOI: 10.1016/j.molbrainres.2005.02.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
240 Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847-860. [PMID: 15607980 DOI: 10.1016/j.cell.2004.11.004] [Cited by in Crossref: 859] [Cited by in F6Publishing: 821] [Article Influence: 50.5] [Reference Citation Analysis]
241 Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, Liou SH, Chang JT, Cheng AJ. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 2005;92:30-5. [PMID: 15583690 DOI: 10.1038/sj.bjc.6602271] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
242 Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2): 289-292 [PMID: 15633234 DOI: 10.3748/wjg.v11.i2.289] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
243 Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, Panda CK, Roychoudhury S. Risk assessment ofp53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern india. Int J Cancer 2005;117:786-93. [DOI: 10.1002/ijc.21263] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
244 Vousden KH, Prives C. P53 and Prognosis. Cell 2005;120:7-10. [DOI: 10.1016/j.cell.2004.12.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 92] [Article Influence: 0.6] [Reference Citation Analysis]
245 Harris S, Gil G, Hu W, Robins H, Bond E, Hirshfield K, Feng Z, Yu X, Teresky A, Bond G, Levine A. Single-Nucleotide Polymorphisms in the p53 Pathway. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:111-9. [DOI: 10.1101/sqb.2005.70.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
246 Tornesello ML, Waddell KM, Duraturo ML, Biryahwaho B, Downing R, Lucas SB, Giani U, Buonaguro L, Buonaguro FM. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detection and Prevention 2005;29:501-8. [DOI: 10.1016/j.cdp.2005.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
247 Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U, Lo-Coco F, Blandino G. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004;18:1804-9. [PMID: 15385938 DOI: 10.1038/sj.leu.2403483] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
248 Fritzsche C, Zeller G, Knaup KX, Roemer K. No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells. Anticancer Drugs 2004;15:679-88. [PMID: 15269599 DOI: 10.1097/01.cad.0000136878.96680.f5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
249 Kojima S, Iwai N, Tago N, Ono K, Ohmi K, Tsujimoto G, Takagi S, Miyazaki S, Nonogi H, Goto Y. p53Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement. Heart. 2004;90:1069-1070. [PMID: 15310710 DOI: 10.1136/hrt.2002.007047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
250 Yamashita K, Yamaguchi Y, Miyazaki M, Nakamura H, Shimizu H, Maeda H. Microfluidic system for DNA sequence detection. Chemical Engineering Journal 2004;101:157-61. [DOI: 10.1016/j.cej.2003.11.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
251 Moll UM, Slade N. p63 and p73: Roles in Development and Tumor Formation. Molecular Cancer Research 2004;2:371-86. [DOI: 10.1158/1541-7786.371.2.7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 1] [Article Influence: 3.4] [Reference Citation Analysis]
252 Craveiro R, Costa S, Pinto D, Salgado L, Carvalho L, Castro C, Bravo I, Lopes C, Silva I, Medeiros R. TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet. 2004;150:116-121. [PMID: 15066318 DOI: 10.1016/j.cancergencyto.2003.08.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
253 Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-dale A, Helland Å. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma: TP53 VARIATION AND ADVANCED OVARIAN CANCER. Hum Mutat 2004;24:21-34. [DOI: 10.1002/humu.20055] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
254 Bonafé M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E, Mishto M, Capri M, Olivieri F, Antonicelli R, Memo M, Uberti D, Nacmias B, Sorbi S, Monti D, Franceschi C. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ 2004;11:962-73. [DOI: 10.1038/sj.cdd.4401415] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 3.2] [Reference Citation Analysis]
255 Zhang ZW, Newcomb P, Hollowood A, Moganaden, Gupta J, Feakins R, Storey A, Farthing MJ, Alderson D, Holly J. A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci 2004;49:254-9. [PMID: 15104366 DOI: 10.1023/b:ddas.0000017447.02220.f5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
256 Zhang ZW, Newcomb P, Hollowood A, Moganaden J, Feakins R, Storey A, Farthing MJ, Alderson D, Holly J. A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci. 2004;49:254-259. [PMID: 15104366 DOI: 10.1023/B: DDAS.0000017447.02220.f5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
257 Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164:1233-41. [PMID: 15039212 DOI: 10.1016/S0002-9440(10)63211-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
258 Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 2003;10:430-435. [PMID: 12824702 DOI: 10.1007/bf02256434] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
259 Porrello A, Soddu S, Zbilut JP, Crescenzi M, Giuliani A. Discrimination of single amino acid mutations of the p53 protein by means of deterministic singularities of recurrence quantification analysis. Proteins 2004;55:743-55. [DOI: 10.1002/prot.20075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
260 McKeon FD. p63 and p73 in tumor suppression and promotion. Cancer Res Treat 2004;36:6-12. [PMID: 20396560 DOI: 10.4143/crt.2004.36.1.6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
261 Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003;10:307-11. [PMID: 14634508 DOI: 10.1007/BF02967650] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 3.6] [Reference Citation Analysis]
262 Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9. [PMID: 14639602 DOI: 10.1002/ijc.11548] [Cited by in Crossref: 271] [Cited by in F6Publishing: 273] [Article Influence: 15.1] [Reference Citation Analysis]
263 Liu S, Bishop WR, Dasmahapatra B, Wang Y. Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance. Drug Dev Res 2004;62:254-72. [DOI: 10.1002/ddr.10362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
264 Hann B, Balmain A. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol. 2003;77:11588-11595. [PMID: 14557644 DOI: 10.1128/jvi.77.21.11588-11595.2003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
265 Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q. p53 Codon 72 Arg Homozygotes Are Associated with an Increased Risk of Cutaneous Melanoma. Journal of Investigative Dermatology 2003;121:1510-4. [DOI: 10.1046/j.1523-1747.2003.12648.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
266 Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C, Lavia P, Levrero M. p73 Is Regulated by Phosphorylation at the G2/M Transition. Journal of Biological Chemistry 2003;278:49196-202. [DOI: 10.1074/jbc.m304921200] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
267 Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resistance Updates 2003;6:323-8. [DOI: 10.1016/j.drup.2003.11.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
268 Riley RM, Jin W, Gibson G. Contrasting selection pressures on components of the Ras-mediated signal transduction pathway in Drosophila. Mol Ecol 2003;12:1315-23. [PMID: 12694293 DOI: 10.1046/j.1365-294x.2003.01741.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
269 Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol. 2003;66:1555-1561. [PMID: 14555234 DOI: 10.1016/S0006-2952(03)00511-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
270 Ueda M, Hung Y, Term Y, Kanda K, Takehara M, Yamashita H, Yamaguchi H, Akise D, Yasuda M, Nishiyama K, Ueki M. Glutathione S-Transferase GSTM1, GSTT1 and p53 Codon 72 Polymorphisms in Human Tumor Cells. Human Cell 2003;16:241-51. [DOI: 10.1111/j.1749-0774.2003.tb00158.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
271 Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387-402. [PMID: 12726864 DOI: 10.1016/s1535-6108(03)00079-5] [Cited by in Crossref: 298] [Cited by in F6Publishing: 277] [Article Influence: 15.7] [Reference Citation Analysis]
272 Clarke AR, Hollstein M. Mouse models with modified p53 sequences to study cancer and ageing. Cell Death Differ 2003;10:443-50. [PMID: 12719721 DOI: 10.1038/sj.cdd.4401188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
273 Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Hayashi S, Hosoda M, Todo S, Nakagawara A. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett 2003;197:105-9. [PMID: 12880968 DOI: 10.1016/s0304-3835(03)00090-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
274 Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003;22:5667-76. [PMID: 12944915 DOI: 10.1038/sj.onc.1206724] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 4.4] [Reference Citation Analysis]
275 Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, Wain JC, Lynch TJ, Liu G, Christiani DC. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer 2003;40:259-66. [PMID: 12781424 DOI: 10.1016/s0169-5002(03)00081-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
276 Lo WD, Akhmametyeva EM, Zhu L, Friesen PD, Chang LS. Induction of apoptosis by the p53-related p73 and partial inhibition by the baculovirus-encoded p35 in neuronal cells. Brain Res Mol Brain Res 2003;113:1-12. [PMID: 12750001 DOI: 10.1016/s0169-328x(03)00052-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
277 Merlano M, Marchetti G. Radiochemotherapy in head and neck cancer. Cancer Treatment Reviews 2003;29:291-6. [DOI: 10.1016/s0305-7372(03)00022-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
278 Kaye FJ, Komiya T. New leads suggest a clinically relevant genotype-phenotype relationship for the p53 gene. J Natl Cancer Inst 2003;95:926-7. [PMID: 12837819 DOI: 10.1093/jnci/95.13.926] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 . P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 2003;13:444-9. [DOI: 10.1046/j.1525-1438.2003.13333.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
280 Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J Biol Chem. 2003;278:34475-34482. [PMID: 12824179 DOI: 10.1074/jbc.m301051200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
281 Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol. 2003;39:222-231. [PMID: 12618194 DOI: 10.1016/s1368-8375(02)00163-x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 5.1] [Reference Citation Analysis]
282 Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta. 2002;326:27-45. [PMID: 12417095 DOI: 10.1016/S0009-8981(02)00297-8] [Cited by in Crossref: 156] [Cited by in F6Publishing: 138] [Article Influence: 8.2] [Reference Citation Analysis]
283 Wang XL, Raveendran M, Wang J. Genetic influence on cigarette-induced cardiovascular disease. Prog Cardiovasc Dis 2003;45:361-82. [PMID: 12704594 DOI: 10.1053/pcad.2003.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
284 Marchetti P, Cannita K, Ricevuto E, De Galitiis F, Di Rocco Z, Tessitore A, Bisegna R, Porzio G, De Rubeis G, Ventura T, Martinotti S, Ficorella C. Prognostic value of p53 molecular status in high-risk primary breast cancer. Annals of Oncology 2003;14:704-8. [DOI: 10.1093/annonc/mdg197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
285 Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, Prives C. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem. 2003;278:27421-27431. [PMID: 12676926 DOI: 10.1074/jbc.M300251200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 2.2] [Reference Citation Analysis]
286 Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10. [DOI: 10.1016/s1535-6108(03)00078-3] [Cited by in Crossref: 304] [Cited by in F6Publishing: 289] [Article Influence: 16.0] [Reference Citation Analysis]
287 Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM. Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73. Journal of Biological Chemistry 2003;278:14230-6. [DOI: 10.1074/jbc.m300357200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
288 Soussi T. p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell 2003;3:303-5. [DOI: 10.1016/s1535-6108(03)00081-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
289 Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357-365. [PMID: 12567188 DOI: 10.1038/ng1093] [Cited by in Crossref: 864] [Cited by in F6Publishing: 850] [Article Influence: 45.5] [Reference Citation Analysis]
290 Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, Rouillard D, Soussi T. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem 2003;278:10546-55. [PMID: 12519788 DOI: 10.1074/jbc.M208233200] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
291 Mitra S, Chatterjee S, Panda CK, Chaudhuri K, Ray K, Bhattacharyya NP, Sengupta A, Roychoudhury S. Haplotype Structure of TP53 Locus in Indian Population and Possible Association with Head and Neck Cancer. Ann Human Genet 2003;67:26-34. [DOI: 10.1046/j.1469-1809.2003.00005.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
292 Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013-1018. [PMID: 12434294 DOI: 10.1038/sj.bjc.6600595] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
293 Bonafè M, Salvioli S, Barbi C, Mishto M, Trapassi C, Gemelli C, Storci G, Olivieri F, Monti D, Franceschi C. p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochemical and Biophysical Research Communications 2002;299:539-41. [DOI: 10.1016/s0006-291x(02)02691-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
294 Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA. 2002;99:14849-14854. [PMID: 12403821 DOI: 10.1073/pnas.222406899] [Cited by in Crossref: 137] [Cited by in F6Publishing: 127] [Article Influence: 6.9] [Reference Citation Analysis]
295 Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196:765-780. [PMID: 12235210 DOI: 10.1084/jem.20020179] [Cited by in Crossref: 227] [Cited by in F6Publishing: 235] [Article Influence: 11.4] [Reference Citation Analysis]
296 Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:6898-907. [DOI: 10.1038/sj.onc.1205563] [Cited by in Crossref: 102] [Cited by in F6Publishing: 84] [Article Influence: 5.1] [Reference Citation Analysis]
297 Bonafè M, Barbi C, Storci G, Salvioli S, Capri M, Olivieri F, Valensin S, Monti D, Gonos ES, De Benedictis G, Franceschi C. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Experimental Gerontology 2002;37:1263-71. [DOI: 10.1016/s0531-5565(02)00137-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
298 Pegoraro RJ, Rom L, Lanning PA, Moodley M, Naiker S, Moodley J. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002;12:383-8. [PMID: 12144687 DOI: 10.1046/j.1525-1438.2002.01109.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.4] [Reference Citation Analysis]
299 Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30. [PMID: 12065086 DOI: 10.1016/s0304-3835(02)00117-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
300 Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002;277:43359-68. [PMID: 12213815 DOI: 10.1074/jbc.M205573200] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 5.2] [Reference Citation Analysis]
301 Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604. [PMID: 12154352 DOI: 10.1038/nrc864] [Cited by in Crossref: 2188] [Cited by in F6Publishing: 2106] [Article Influence: 109.4] [Reference Citation Analysis]
302 Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S, Dinshaw K. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol. 2002;86:157-162. [PMID: 12144822 DOI: 10.1006/gyno.2002.6735] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.0] [Reference Citation Analysis]
303 Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002;2:605-15. [DOI: 10.1038/nrc861] [Cited by in Crossref: 396] [Cited by in F6Publishing: 394] [Article Influence: 19.8] [Reference Citation Analysis]
304 Stiewe T, Pützer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237-45. [PMID: 11859406 DOI: 10.1038/sj.cdd.4400995] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 5.4] [Reference Citation Analysis]
305 Mcgregor JM, Harwood CA, Brooks L, Kelly DA, O’nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM, Storey A, Crook T, Fisher SA. Relationship Between p53 Codon 72 Polymorphism and Susceptibility to Sunburn and Skin Cancer. Journal of Investigative Dermatology 2002;119:84-90. [DOI: 10.1046/j.1523-1747.2002.01655.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 302] [Article Influence: 3.1] [Reference Citation Analysis]
306 Cairey-remonnay S, Humbey O, Mougin C, Algros MP, Mauny F, Kanitakis J, Euvrard S, Laurent R, Aubin F. TP53 Polymorphism of Exon 4 at Codon 72 in Cutaneous Squamous Cell Carcinoma and Benign Epithelial Lesions of Renal Transplant Recipients and Immunocompetent Individuals: Lack of Correlation with Human Papillomavirus Status11This work was presented in part at the 19th International Papillomavirus Conference in Florianopolis, Brazil, September 1–7, 2001. Journal of Investigative Dermatology 2002;118:1026-31. [DOI: 10.1046/j.1523-1747.2002.01787.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
307 Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Letters 2002;179:175-83. [DOI: 10.1016/s0304-3835(01)00867-9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 4.6] [Reference Citation Analysis]
308 Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002;22:2575-85. [PMID: 11909952 DOI: 10.1128/MCB.22.8.2575-2585.2002] [Cited by in Crossref: 133] [Cited by in F6Publishing: 132] [Article Influence: 6.7] [Reference Citation Analysis]
309 Münger K. Disruption of Oncogene/Tumor Suppressor Networks During Human Carcinogenesis. Cancer Investigation 2002;20:71-81. [DOI: 10.1081/cnv-120000369] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
310 Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40. [PMID: 11902578 DOI: 10.1038/35106009] [Cited by in Crossref: 444] [Cited by in F6Publishing: 405] [Article Influence: 22.2] [Reference Citation Analysis]
311 Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer: . Current Opinion in Infectious Diseases 2002;15:101-14. [DOI: 10.1097/00001432-200204000-00002] [Cited by in Crossref: 144] [Cited by in F6Publishing: 116] [Article Influence: 7.2] [Reference Citation Analysis]
312 Moll UM, Erster S, Zaika A. p53, p63 and p73--solos, alliances and feuds among family members. Biochim Biophys Acta 2001;1552:47-59. [PMID: 11825686 DOI: 10.1016/s0304-419x(01)00036-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 35] [Article Influence: 0.4] [Reference Citation Analysis]
313 Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002;277:18817-26. [PMID: 11893750 DOI: 10.1074/jbc.M201405200] [Cited by in Crossref: 159] [Cited by in F6Publishing: 157] [Article Influence: 8.0] [Reference Citation Analysis]
314 Balint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA. 2002;99:3529-3534. [PMID: 11891335 DOI: 10.1073/pnas.062491899] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 3.6] [Reference Citation Analysis]
315 Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutation Research/Reviews in Mutation Research 2002;511:45-62. [DOI: 10.1016/s1383-5742(01)00075-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
316 Mcdonald SP, Hoy WE, Maguire GP, Duarte NL, Wilcken DEL, Wang XL. The p53Pro72Arg Polymorphism is Associated with Albuminuria among Aboriginal Australians. JASN 2002;13:677-83. [DOI: 10.1681/asn.v133677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
317 Deb D, Scian M, Roth KE, Li W, Keiger J, Chakraborti AS, Deb SP, Deb S. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Oncogene 2002;21:176-89. [PMID: 11803461 DOI: 10.1038/sj.onc.1205035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
318 O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, Reddy A, Tidy JA, Evans D, Farrell PJ, Evans A, Gasco M, Gusterson B, Crook T. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer 2001;85:1551-6. [PMID: 11720444 DOI: 10.1054/bjoc.2001.2138] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
319 Watanabe K, Ozaki T, Nakagawa T, Miyazaki K, Takahashi M, Hosoda M, Hayashi S, Todo S, Nakagawara A. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J Biol Chem 2002;277:15113-23. [PMID: 11844794 DOI: 10.1074/jbc.M111281200] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 2.6] [Reference Citation Analysis]
320 Stiewe T, Theseling CC, Pützer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002;277:14177-85. [PMID: 11844800 DOI: 10.1074/jbc.M200480200] [Cited by in Crossref: 124] [Cited by in F6Publishing: 131] [Article Influence: 6.2] [Reference Citation Analysis]
321 Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (oscc) patients of Eastern India. Int J Cancer 2002;97:649-53. [DOI: 10.1002/ijc.10112] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 3.9] [Reference Citation Analysis]
322 Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, Blandino G. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 2001;21:8461-70. [PMID: 11713281 DOI: 10.1128/MCB.21.24.8461-8470.2001] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 4.2] [Reference Citation Analysis]
323 Sayan AE, Sayan BS, Findikli N, Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene. 2001;20:5111-5117. [PMID: 11526499 DOI: 10.1038/sj.onc.1204669] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 1.8] [Reference Citation Analysis]
324 Sigal A, Matas D, Almog N, Goldfinger N, Rotter V. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis. Oncogene 2001;20:4891-8. [PMID: 11521201 DOI: 10.1038/sj.onc.1204724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
325 Zhu J, Nozell S, Wang J, Jiang J, Zhou W, Chen X. p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 2001;20:4050-7. [PMID: 11494133 DOI: 10.1038/sj.onc.1204516] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
326 Chène P. The role of tetramerization in p53 function. Oncogene 2001;20:2611-7. [PMID: 11420672 DOI: 10.1038/sj.onc.1204373] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 8.0] [Reference Citation Analysis]
327 Chen X, Zheng Y, Zhu J, Jiang J, Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 2001;20:769-74. [PMID: 11314010 DOI: 10.1038/sj.onc.1204149] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.1] [Reference Citation Analysis]
328 Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A, Blandino G. From p63 to p53 across p73. FEBS Lett 2001;490:163-70. [PMID: 11223031 DOI: 10.1016/s0014-5793(01)02119-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 3.1] [Reference Citation Analysis]
329 Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1:199-207. [PMID: 11252895 DOI: 10.1038/35043127] [Cited by in Crossref: 326] [Cited by in F6Publishing: 324] [Article Influence: 15.5] [Reference Citation Analysis]
330 Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001;21:1874-1887. [PMID: 11238924 DOI: 10.1128/mcb.21.5.1874-1887.2001] [Cited by in Crossref: 312] [Cited by in F6Publishing: 311] [Article Influence: 14.9] [Reference Citation Analysis]
331 Luo J, Yang Q, Tong W, Hergenhahn M, Wang Z, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001;20:320-8. [DOI: 10.1038/sj.onc.1204080] [Cited by in Crossref: 107] [Cited by in F6Publishing: 97] [Article Influence: 5.1] [Reference Citation Analysis]
332 Lemasson I, Nyborg JK. Human T-cell leukemia virus type I tax repression of p73beta is mediated through competition for the C/H1 domain of CBP. J Biol Chem 2001;276:15720-7. [PMID: 11279015 DOI: 10.1074/jbc.M100131200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
333 Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164-73. [PMID: 11278685 DOI: 10.1074/jbc.M010484200] [Cited by in Crossref: 293] [Cited by in F6Publishing: 294] [Article Influence: 14.0] [Reference Citation Analysis]
334 Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9. [PMID: 11101847 DOI: 10.1038/82617] [Cited by in Crossref: 227] [Cited by in F6Publishing: 234] [Article Influence: 10.8] [Reference Citation Analysis]
335 Riazuddin S, Castelein CM, Ahmed ZM, Lalwani AK, Mastroianni MA, Naz S, Smith TN, Liburd NA, Friedman TB, Griffith AJ, Riazuddin S, Wilcox ER. Dominant modifier DFNM1 suppresses recessive deafness DFNB26. Nat Genet 2000;26:431-4. [PMID: 11101839 DOI: 10.1038/82558] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 4.1] [Reference Citation Analysis]
336 Soengas MS, Lowe SW. p53 and p73: seeing double? Nat Genet 2000;26:391-2. [DOI: 10.1038/82497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]